Friday, 16 October 2026European Markets

EBUSCO HOLDING Stock Was 11.63% Up On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with EBUSCO HOLDING (EBUS.AS) rising 11.63% to €7.87 on Tuesday while AEX-Index jumped 0.19% to €736.77.

EBUSCO HOLDING's last close was €7.05, 60.17% below its 52-week high of €17.70.

About EBUSCO HOLDING

Ebusco Holding N.V., together with its subsidiaries, develops, manufactures, and distributes zero emission buses, batteries, and charging systems in the Netherlands, Belgium, France, Germany, Norway, Switzerland, and Denmark. It also sells ancillary products and services; and provides electric vehicle ecosystem repair and maintenance services. Ebusco Holding N.V. was founded in 2010 and is headquartered in Deurne, the Netherlands.

Earnings Per Share

As for profitability, EBUSCO HOLDING has a trailing twelve months EPS of €-1.11.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -20.25%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EBUSCO HOLDING's stock is considered to be oversold (<=20).

Volume

Today's last reported volume for EBUSCO HOLDING is 893622 which is 411.47% above its average volume of 174715.

Revenue Growth

Year-on-year quarterly revenue growth grew by 12.5%, now sitting on 116.25M for the twelve trailing months.

More news about EBUSCO HOLDING (EBUS.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com